Fascial Plane Botulinum Injection for Uniform Migraine Nerve Coverage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current FDA-approved methods for treating migraines using Botulinum toxin suffer from limited dosing and administration volume, leading to sporadic treatment coverage of sensory nerves and unwanted side effects such as muscle paralysis.
Innovation Solution
Administer higher total doses and larger volumes of Botulinum toxin extramuscularly to specific nerve clusters and layers in the head, targeting sensory nerves responsible for migraine symptoms while minimizing muscle paralysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If higher total doses and larger volumes of Botulinum toxin are administered extramuscularly to specific nerve clusters and layers, then treatment coverage of sensory nerves is improved and uniformity is enhanced, but the risk of muscle paralysis and other side effects increases
Solution Approach 1:
The patent applies local quality by targeting specific nerve clusters and fascial layers (fronto-fascial, temporoparietal-fascial, occipito-fascial) with precise extramuscular injections. Each region receives customized dosing (40-60 units fronto-fascial, 40-70 units temporoparietal-fascial, 60-110 units occipito-fascial) concentrated at nerve exit points and along nerve pathways, ensuring uniform sensory nerve coverage while limiting toxin spread to adjacent muscles.
Solution Approach 2:
The patent uses fascial layers as an intermediary target for toxin delivery. By injecting extramuscularly into the fascial plane rather than directly into muscle, the toxin is delivered to sensory nerves that run within the fascia, serving as a mediator between the injection site and the nerve targets while protecting surrounding muscle tissue from direct toxin exposure.
2Reliability
If higher total doses of Botulinum toxin are used, then migraine treatment efficacy is improved, but unwanted side effects such as muscle paralysis increase
Solution Approach 1:
The patent substitutes the traditional intramuscular injection approach with an extramuscular fascial plane injection approach. This mechanical substitution allows higher total doses (140-240 units) to be administered while the toxin remains in the fascial plane rather than diffusing into muscle tissue, maintaining efficacy while preventing muscle paralysis side effects.
3Reliability
If larger volumes of Botulinum toxin are administered, then sensory nerve coverage is improved, but diffusion to unwanted areas increases causing side effects
Solution Approach 1:
The patent utilizes the fascial layer as a confined compartment that acts as a natural barrier. By injecting into the fascial plane, the toxin is contained within this thin film-like structure, preventing excessive diffusion into surrounding tissues and muscles while still allowing adequate spread along the nerve pathways for comprehensive coverage.
Data Source
Figure 1A~1B
Figure 2A
Figure 2B
AI summary
The present specification discloses methods and uses for treating a migraine disorder. The disclosed method comprising extramuscularly administering a Botulinum toxin to an individual in one of more areas of a fronto-fascial layer located in a frontal head region of the individual, one of more areas of a temporoparietal-fascial layer located in a temporal head region of the individual, and one or more areas of an occipito-fascial layer located in an occipital head region of the individual. The disclosed methods and uses further comprise extramuscularly administering a Botulinum toxin to one or more nerve exit points, one or more subcutaneous locations in the head and neck as well as one or more sites of an epicranial aponeurosis and/or intramuscularly administration to one or more locations within the left /right Splenius Capitus, the left/right Masseter, the left/right Trapezius muscles, or any combination thereof.